Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial
Lotta Ulander(Helsinki University Hospital), Juha Sinisalo(University of Helsinki), Pasi P. Karjalainen(Helsinki University Hospital), Kristiina Silventoinen(Helsinki University Hospital), Katariina Nurmi(University of Helsinki), Heli Tolppanen(Inserm), Riitta Paakkanen(Helsinki University Hospital), Teemu E.I. Drews(South Karelia Central Hospital), Tuomo Nieminen(Päijät-Hämeen Keskussairaala), Jouni Kuusisto(Helsinki University Hospital), Jukka Lehtonen(Helsinki University Hospital), Miika Koskinen(University of Helsinki), Jaana Yrjölä(Kymenlaakson keskussairaala), Kari K. Eklund(University of Helsinki), Otto Hartman(Helsinki University Hospital), Seppo Utriainen(South Karelia Central Hospital), Ismo Anttila(Seinäjoki University of Applied Sciences), Ransu Ryysy(Kymenlaakson keskussairaala), Olli Anttonen(Päijät-Hämeen Keskussairaala), Petri T. Kovanen(Wihuri Research Institute), Tuomas T. Rissanen(University of Eastern Finland)
Cited by 29
Related Papers
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
(untitled)
|Edinburgh Research Explorer (University of Edinburgh)|0|2.3k
Lipoprotein(a) as a cardiovascular risk factor: current status
|European Heart Journal|2010|1.8k
Physiological changes in pregnancy
|Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa|2016|1.4k